METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Clinical trials for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: experimental drug enters human testing
Disease control Recruiting nowThis early-phase study tests an experimental drug called mevrometostat in adults with certain advanced cancers that have stopped responding to standard treatments. The study is currently enrolling men with castration-resistant prostate cancer. Participants receive the drug by mou…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-phase trial is testing a new drug called xaluritamig (AMG 509) in 40 adults with metastatic castration-resistant prostate cancer, a type that has spread and no longer responds to hormone therapy. The main goal is to check the drug's safety and how it moves through the …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo aims to shrink Hard-to-Treat prostate tumors
Disease control Recruiting nowThis study tests a new drug called REGN5678, given alone or with another drug (cemiplimab), in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to see if the combination can safely shrink tumors by helping the immune system attack cancer c…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New hope for tough prostate cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug called opevesostat (plus hormone replacement therapy) against two standard treatments (abiraterone or enzalutamide) in about 1,300 men with metastatic castration-resistant prostate cancer that got worse after one prior hormone therapy. The goal is to s…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Engineered t cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis study tests a new treatment called AB-3028, which uses a patient's own immune cells (T cells) that have been modified in a lab to better attack prostate cancer cells. It is for men with metastatic castration-resistant prostate cancer, a type that has stopped responding to ho…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Arsenal Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase study tests a new radioactive drug (161Tb-PSMA-I&T) in 12 Taiwanese men with metastatic castration-resistant prostate cancer that has stopped responding to hormone therapy. The drug seeks out prostate cancer cells and delivers targeted radiation. The main goal is…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: National Taiwan University Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New prostate cancer drug enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new oral drug called INR731, alone or with standard hormone therapy drugs, in 208 men with metastatic prostate cancer that no longer responds to hormone treatment. The main goals are to check safety, find the right dose, and see if the drug shows an…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New radioactive drug aims to shrink hard-to-treat prostate cancer
Disease control Recruiting nowThis early study tests a new drug called 3D1015 in men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells. The main goals are to check safety and find the best dose. About 8 men will take part.
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Chunjing Yu • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can green tea and quercetin boost chemo for advanced prostate cancer?
Disease control Recruiting nowThis study tests whether adding natural products green tea and quercetin to standard chemotherapy (docetaxel) can improve treatment for men with advanced prostate cancer that no longer responds to hormone therapy. About 99 participants will receive either the natural supplements …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Charles Drew University of Medicine and Science • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New hope for tough prostate cancer? early trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called KTX-2001, alone or with another drug (darolutamide), in men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The main goals are to check safety, find the right dose, and …
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could gut bacteria help fight prostate cancer? new trial tests antibiotic combo
Disease control Recruiting nowThis trial tests whether a short course of four antibiotics can make the standard drug enzalutamide work better in men with metastatic castration-resistant prostate cancer. About 39 men will receive the antibiotics plus enzalutamide to see if the combination is safe and can shrin…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug NX-1607 enters first human trials
Disease control Recruiting nowThis early-stage trial tests a new drug called NX-1607 in adults with advanced cancers that have not responded to standard treatments. The study aims to find a safe dose and see if the drug can shrink tumors. It includes people with several cancer types, such as ovarian, lung, an…
Matched conditions: METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
Phase: PHASE1 • Sponsor: Nurix Therapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC